Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

iPS Cell Differentiation

iPS Cell Differentiation

The ability of induced pluripotent stem cells or iPSCs to differentiate into most body cell types has stimulated repair and regenerative medicine research over the past few decades. iPSC-derived blood cells, hepatocytes, beta islet cells, cardiomyocytes, neurons, and other cell types can repair injuries or regenerate damaged tissue in diseases such as diabetes and neurodegenerative disorders.

Induced Pluripotent Stem Cells

Induced Pluripotent Stem Cells

Stem cells are undifferentiated cells that divide and produce different types of cells. Ordinarily, cells that have differentiated into a specific cell type are post-mitotic—that is, they no longer divide. However, scientists have found a way to reprogram these mature cells so that they “de-differentiate” and return to an unspecialized, proliferative state. These cells are also pluripotent like embryonic stem cells—able to produce all cell types—and are therefore called induced pluripotent stem...

Induced Pluripotent Stem Cells

Induced Pluripotent Stem Cells

Stem cells are undifferentiated cells that divide and produce different cell types. Ordinarily, cells that have differentiated into a specific cell type are terminally differentiated; however, scientists have found a way to reprogram these mature cells so that they dedifferentiate and return to an unspecialized, proliferative state. These cells are pluripotent like embryonic stem cells—able to produce all cell types—and are called induced pluripotent stem cells (iPSCs).
Somatic cells are...

Induced Pluripotent Stem Cells

Induced Pluripotent Stem Cells

Stem cells are undifferentiated cells that divide and produce different types of cells. Ordinarily, cells that have differentiated into a specific cell type are post-mitotic—that is, they no longer divide. However, scientists have found a way to reprogram these mature cells so that they “de-differentiate” and return to an unspecialized, proliferative state. These cells are also pluripotent like embryonic stem cells—able to produce all cell types—and are therefore called induced pluripotent stem...

Stem Cell Culture

Stem Cell Culture

Stem cell research aims to find ways to use stem cells to regenerate and repair cellular damage. Over time, most adult cells undergo the wear and tear of aging and lose their ability to divide and repair themselves. Stem cells do not display a particular morphology or function. Adult stem cells, which exist as a small subset of cells in most tissues, keep dividing and can differentiate into a number of specialized cells generally formed by that tissue. These cells enable the body to renew and...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Serum Circulating Interleukin-8 DNA Levels Are Elevated in Patients With Palmoplantar Pustulosis.

The Journal of dermatology·2026

Same author

Bullous pemphigoid and Graves' disease developing during prolonged remission of pemphigus vulgaris.

European journal of dermatology : EJD·2026

Same author

Blockade for CD276-mediated suppression of tumor-specific cytotoxic T lymphocytes may contribute to achieving durable responses with immune checkpoint inhibitors.

The Journal of investigative dermatology·2026

Same author

Clinical utility of comprehensive genomic profiling in 175 Japanese patients with advanced skin malignancies refractory to standard therapies.

JAAD international·2026

Same author

Case of generalized morphea complicated with systemic sclerosis.

Dermatology reports·2026

Same author

Cutaneous Phaeohyphomycosis Caused by Exophiala jeanselmei.

Medical mycology journal·2026

Search research articles

Related Experiment Video

Updated: Jun 3, 2026

Preparation of Tumor Antigen-loaded Mature Dendritic Cells for Immunotherapy

Preparation of Tumor Antigen-loaded Mature Dendritic Cells for Immunotherapy

Published on: August 1, 2013

Immunotherapy with pluripotent stem cell-derived dendritic cells.

Satoru Senju¹, Yusuke Matsunaga, Satoshi Fukushima

¹Department of Immunogenetics, Graduate School of Medical Sciences, Kumamoto University, 1-1-1 Honjo, Kumamoto, 860-8556, Japan. senjusat@gpo.kumamoto-u.ac.jp

Seminars in Immunopathology

|April 5, 2011

Summary

This summary is machine-generated.

Generating dendritic cells (DC) from pluripotent stem cells offers a promising solution for cancer immunotherapy and autoimmune disease treatments. This method overcomes limitations associated with using patient monocytes for cell therapy.

More Related Videos

Tractable In Vivo Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells

Tractable In Vivo Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells

Published on: August 1, 2025

Generation of a Novel Dendritic-cell Vaccine Using Melanoma and Squamous Cancer Stem Cells

Generation of a Novel Dendritic-cell Vaccine Using Melanoma and Squamous Cancer Stem Cells

Published on: January 6, 2014

Related Experiment Videos

Last Updated: Jun 3, 2026

Preparation of Tumor Antigen-loaded Mature Dendritic Cells for Immunotherapy

Preparation of Tumor Antigen-loaded Mature Dendritic Cells for Immunotherapy

Published on: August 1, 2013

Tractable In Vivo Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells

Tractable In Vivo Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells

Published on: August 1, 2025

Generation of a Novel Dendritic-cell Vaccine Using Melanoma and Squamous Cancer Stem Cells

Generation of a Novel Dendritic-cell Vaccine Using Melanoma and Squamous Cancer Stem Cells

Published on: January 6, 2014

Area of Science:

Immunology
Cell Biology
Biotechnology

Background:

Dendritic cells (DCs) are crucial for T cell priming and hold potential for anti-cancer immunotherapy, autoimmune disease treatment, and transplantation medicine.
Current methods for generating DCs for therapy rely on peripheral blood monocytes, which have limitations in quantity and donor-dependent differentiation potential.
The need for alternative, scalable sources of functional DCs is critical for advancing cell-based therapies.

Purpose of the Study:

To review established methods for generating functional dendritic cells (DCs) from pluripotent stem cells (PSCs).
To address the limitations of current monocyte-derived DC generation for therapeutic applications.
To highlight the potential of PSC-derived DCs in various medical fields, including immunotherapy and regenerative medicine.

Main Methods:

Review of scientific literature detailing protocols for differentiating mouse and human pluripotent stem cells into dendritic cells.
Analysis of methods focusing on the functional capacity of generated DCs, including their ability to prime T cells.
Comparison of PSC-derived DC generation techniques regarding efficiency, scalability, and clinical applicability.

Main Results:

Established protocols exist for generating functional dendritic cells from both mouse and human pluripotent stem cells.
Pluripotent stem cell-derived DCs demonstrate T cell priming capabilities, suggesting therapeutic potential.
These methods offer a scalable and potentially more consistent source of DCs compared to traditional monocyte isolation.

Conclusions:

Generating dendritic cells from pluripotent stem cells presents a viable alternative to monocyte-derived DCs.
This approach could overcome current limitations in cell therapy, enhancing the efficacy of immunotherapies and treatments for autoimmune diseases.
Further research and clinical translation of PSC-derived DC therapies are warranted.